Aterido, Adrià
Palau, Núria
Domènech, Eugeni
Nos Mateu, Pilar
Gutiérrez, Ana
Gomollón, Fernando
Mendoza, Juan L.
Garcia-Planella, Esther
Barreiro-de Acosta, Manuel
Muñoz, Fernando
Vera, Maribel
Saro, Cristina
Esteve, Maria
Andreu, Montserrat
Chaparro, María
Panés, Julián
García-Sánchez, Valle
López-Lasanta, María
Pluma, Andrea
Codó, Laia
García-Montero, Andrés
Manyé, Josep
Gisbert, Javier P.
Marsal, Sara
Julià, Antonio http://orcid.org/0000-0001-6064-3620
Funding for this research was provided by:
Generalitat de Catalunya (00587)
Ministerio de Economía y Competitividad (PSE-010000-2006-6)
Spanish Ministry of Economic Affairs and Competitiveness
Article History
Received: 15 June 2018
Revised: 28 March 2019
Accepted: 2 April 2019
First Online: 2 May 2019
Compliance with ethical standards
:
: Dr. Panés has received consulting fees from Abbvie, Boehringer-Ingelheim, Celgene, Ferring, Genentech, GSK, Janssen, MSD, Oppilan, Pfizer, Second Genome, Roche, Takeda, Theravance and TiGenix. Speaker fees from Abbvie, Ferring, Janssen, MSD, and Takeda. Dr. Gisbert has served as a speaker, a consultant and advisory member for or has received research funding from MSD, Abbvie, Hospira, Pfizer, Kern Pharma, Biogen, Takeda, Janssen, Roche, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, and Vifor Pharma. Dr. Barreiro-de Acosta has served as a speaker, a consultant and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Takeda, Janssen, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Gebro Pharma, Otsuka Pharmaceutical, and Vifor Pharma. The remaining authors declare that they have no conflict of interest.
: Informed consent was obtained from all participants, and protocols were reviewed and approved by local institutional review boards. The present study was conducted according to the Declaration of Helsinki principles.